5414x Direct

: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update

: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year. : Established a strategic collaboration with Cepheid (a

: Continued advancement in national programs like NIHR Bioresource. Strategic and Operational Developments : Established a strategic collaboration with Cepheid (a

: £13.0 million (+52.9%), driven by AMR and EMEAI growth. : Established a strategic collaboration with Cepheid (a

The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25